Placebo + SPR720 500 mg + SPR720 1000 mg
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Conditions
Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Trial Timeline
Dec 14, 2022 → Dec 2, 2024
NCT ID
NCT05496374About Placebo + SPR720 500 mg + SPR720 1000 mg
Placebo + SPR720 500 mg + SPR720 1000 mg is a phase 2 stage product being developed by Spero Therapeutics for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD). The current trial status is completed. This product is registered under clinical trial identifier NCT05496374. Target conditions include Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD).
What happened to similar drugs?
0 of 4 similar drugs in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05496374 | Phase 2 | Completed |
Competing Products
8 competing products in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rifabutin | Pfizer | Phase 3 | 40 |
| ALIS + Azithromycin + Ethambutol + ELC | Insmed | Phase 3 | 37 |
| ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS) | Insmed | Phase 3 | 37 |
| LAI plus multi-drug regimen | Insmed | Phase 2 | 32 |
| Liposomal amikacin for inhalation (LAI) + placebo | Insmed | Phase 2 | 32 |
| LAI (Liposomal Amikacin for Inhalation) 590 mg | Insmed | Phase 3 | 37 |
| Molgramostim nebulizer solution | Savara | Phase 2 | 21 |
| Inhaled molgramostim + Antimycobacterial regimen | Savara | Phase 2 | 29 |